PBYI logo

PBYIPuma Biotechnology Inc

$7.27
$0.035
(0.48%)
Today
Updated: 01:56 PM EDT
EarningsAug 6
Mkt Cap$368M
Vol146,863.00
47

Neutral Sentiment

How do you feel about PBYI?

News
all
press releases
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Zacks
News Placeholder
More News
News Placeholder
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees...
Business Wire
News Placeholder
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Zacks
News Placeholder
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +68.00% and +14.23%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Puma Biotechnology Reports First Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for the first quarter 2026 compared to the first quarter 2025. Product revenue, net consists entirely of revenue...
Business Wire
News Placeholder
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees...
Business Wire
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -10.53% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday
Puma Biotechnology (NASDAQ:PBYI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-puma-biotechnology-inc-stock...
MarketBeat
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.